4.2 Article

Secondary hypoadrenalism

期刊

PITUITARY
卷 11, 期 2, 页码 147-154

出版社

SPRINGER
DOI: 10.1007/s11102-008-0108-4

关键词

cosyntropin stimulation test; insulin tolerance test; metyrapone test; secondary adrenal insufficiency

向作者/读者索取更多资源

Secondary adrenal insufficiency (SAI) is a clinical disorder that results from hypothalamic or hypophyseal damage or from prolonged administration of supraphysiological doses of glucocorticoids. Since glucocorticoids are widely used for a variety of diseases, the prevalence of SAI is by far exceeding that of primary adrenal insufficiency. Although the presentation of adrenal insufficiency may be insidious and difficult to recognize, an appropriate adrenocortical hormone replacement could lead to a normal quality of life and longevity can be achieved. The spectrum of adrenal insufficiency ranges from overt adrenal crises to subtle dysfunctions in asymptomatic patients who may be at risk of developing acute adrenal insufficiency since their hypothalamic-pituitary-adrenal (HPA) axis cannot appropriately react to stress. Thus, identification of patients with subtle abnormalities of the HPA is mandatory for avoiding this life-threatening event in stressful conditions. The optimal tests and the optimal testing sequence for adrenal insufficiency are still matter of debate. Insulin tolerance test (ITT) could be the gold standard, as it tests the whole HPA axis, but there are some patients who pass the ITT failing the ACTH test. Various alternatives to the ITT, including the standard cosyntropin stimulation test (SST) and low-dose SST, have been proposed since the adrenal gland in SAI loses the capacity for a prompt response to ACTH stimulation. The standard ACTH dose, but not the 1 mu g dose, increases adrenal blood flow and this may contribute to produce an early cortisol response of greater magnitude. Moreover, the loss of the early cortisol response to ACTH stimulation could be a specific property of adrenal insufficiency, thus being a sensitive and early marker of failing adrenal function. While the results of the SSTs are often positive in patients with long-standing and severe disease, in patients with mild or recent-onset SAI these tests, using either 250 mu g or 1 mu g ACTH, tend to give normal results; thus, a negative cosyntropin test result does not rule out the possibility of SAL Further studies with a systematic comparison of the different tests in large series of patients submitted to a prolonged follow-up are needed to solve the controversy of the optimal diagnostic strategy of SAI.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Peripheral Vascular Disease

Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy

Mirko Parasiliti-Caprino, Barbara Lucatello, Chiara Lopez, Jacopo Burrello, Francesca Maletta, Marinella Mistrangelo, Enrica Migliore, Francesco Tassone, Antonio La Grotta, Anna Pia, Giuseppe Reimondo, Roberta Giordano, Giuseppe Giraudo, Alessandro Piovesan, Giovannino Ciccone, Desiree Deandreis, Paolo Limone, Fabio Orlandi, Giorgio Borretta, Marco Volante, Paolo Mulatero, Mauro Papotti, Gianluca Aimaretti, Massimo Terzolo, Mario Morino, Barbara Pasini, Franco Veglio, Ezio Ghigo, Emanuela Arvat, Mauro Maccario

HYPERTENSION RESEARCH (2020)

Article Oncology

Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study

Barbara Altieri, Silviu Sbiera, Sabine Herterich, Silvia De Francia, Silvia Della Casa, Anna Calabrese, Alfredo Pontecorvi, Marcus Quinkler, Tina Kienitz, Massimo Mannelli, Letizia Canu, Anna Angelousi, Vasileios Chortis, Matthias Kroiss, Massimo Terzolo, Martin Fassnacht, Cristina L. Ronchi

CANCERS (2020)

Article Oncology

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience

Marta Lagana, Salvatore Grisanti, Deborah Cosentini, Vittorio Domenico Ferrari, Barbara Lazzari, Roberta Ambrosini, Chiara Sardini, Alberto Dalla Volta, Carlotta Palumbo, Pietro Luigi Poliani, Massimo Terzolo, Sandra Sigala, Guido Alberto Massimo Tiberio, Alfredo Berruti

CANCERS (2020)

Article Health Care Sciences & Services

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question

Vittoria Basile, Soraya Puglisi, Barbara Altieri, Letizia Canu, Rossella Libe, Filippo Ceccato, Felix Beuschlein, Marcus Quinkler, Anna Calabrese, Paola Perotti, Paola Berchialla, Ulrich Dischinger, Felix Megerle, Eric Baudin, Isabelle Bourdeau, Andre Lacroix, Paola Loli, Alfredo Berruti, Darko Kastelan, Harm R. Haak, Martin Fassnacht, Massimo Terzolo

Summary: The study found that extending adjuvant mitotane treatment over two years did not show significant survival advantage in patients with ACC, and the relationship between treatment duration and the frequency of ACC recurrence was not linear.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Article Health Care Sciences & Services

Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications

Marco Volante, Ida Rapa, Jasna Metovic, Francesca Napoli, Cristian Tampieri, Eleonora Duregon, Massimo Terzolo, Mauro Papotti

Summary: This study identified dysregulation of 14 genes in adrenocortical carcinomas, with most being downregulated. However, three exceptions showed increased expression levels, including HAS-1, laminin alpha 3, and osteopontin genes, which could serve as potential diagnostic and prognostic biomarkers in adrenal cortical tumors.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Article Biology

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma

Sarah Allegra, Soraya Puglisi, Irene Brescia, Francesco Chiara, Vittoria Basile, Anna Calabrese, Giuseppe Reimondo, Silvia De Francia

Summary: Gender is an important factor in pharmacological management and treatment outcomes. Research on adrenocortical carcinoma patients shows that gender can predict mitotane concentrations and affect the achievement of therapeutic targets, with female sex potentially being a risk factor for treatment failure.

LIFE-BASEL (2021)

Article Medicine, General & Internal

Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors A Cross-Sectional Multicenter Study

Alessandro Prete, Anuradhaa Subramanian, Irina Bancos, Vasileios Chortis, Stylianos Tsagarakis, Katharina Lang, Magdalena Macech, Danae A. Delivanis, Ivana D. Pupovac, Giuseppe Reimondo, Ljiljana Marina, Timo Deutschbein, Maria Balomenaki, Michael W. O'Reilly, Lorna C. Gilligan, Carl Jenkinson, Tomasz Bednarczuk, Catherine D. Zhang, Tina Dusek, Aristidis Diamantopoulos, Miriam Asia, Agnieszka Kondracka, Dingfeng Li, Jimmy R. Masjkur, Marcus Quinkler, Grethe A. Ueland, M. Conall Dennedy, Felix Beuschlein, Antoine Tabarin, Martin Fassnacht, Miomira Ivovic, Massimo Terzolo, Darko Kastelan, William F. Young, Konstantinos N. Manolopoulos, Urszula Ambroziak, Dimitra A. Vassiliadi, Angela E. Taylor, Alice J. Sitch, Krishnarajah Nirantharakumar, Wiebke Arlt

Summary: Patients with mild autonomous cortisol secretion (MACS), especially MACS-2 and CS, have a higher prevalence and severity of hypertension and type 2 diabetes. MACS predominantly affects women and regular assessment for cardiometabolic diseases is warranted.

ANNALS OF INTERNAL MEDICINE (2022)

Article Oncology

A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy

Letizia Canu, Soraya Puglisi, Paola Berchialla, Giuseppina De Filpo, Francesca Brignardello, Francesca Schiavi, Alfonso Massimiliano Ferrara, Stefania Zovato, Michaela Luconi, Anna Pia, Marialuisa Appetecchia, Emanuela Arvat, Claudio Letizia, Mauro Maccario, Mirko Parasiliti-Caprino, Barbara Altieri, Antongiulio Faggiano, Roberta Modica, Valentina Morelli, Maura Arosio, Uberta Verga, Micaela Pellegrino, Luigi Petramala, Antonio Concistre, Paola Razzore, Tonino Ercolino, Elena Rapizzi, Mario Maggi, Antonio Stigliano, Jacopo Burrello, Massimo Terzolo, Giuseppe Opocher, Massimo Mannelli, Giuseppe Reimondo

Summary: This study was the first to assess the risk of developing a second malignant tumor in PPGL patients, showing that they have a higher incidence of additional malignant tumors compared to the general population who had a first malignancy. The main tumors associated with second malignancies differed by gender, with an impact on surveillance strategy.

CANCERS (2021)

Review Oncology

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies

Marco Lo Iacono, Soraya Puglisi, Paola Perotti, Laura Saba, Jessica Petiti, Claudia Giachino, Giuseppe Reimondo, Massimo Terzolo

Summary: Mitotane is the only approved drug for the treatment of advanced adrenocortical carcinoma and is increasingly used for postoperative adjuvant therapy. It destroys the adrenal cortex, impairs steroidogenesis, and leads to cell death by deregulating cytochromes P450 enzymes, depolarizing mitochondrial membranes, and accumulating free cholesterol. The exact mechanism of mitotane's action is still unclear, and the variability in in vitro experimental conditions could impact the significance of identified molecular mechanisms.

CANCERS (2021)

Article Biochemistry & Molecular Biology

From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma

Mirko Parasiliti-Caprino, Fabio Bioletto, Chiara Lopez, Martina Bollati, Francesca Maletta, Marina Caputo, Valentina Gasco, Antonio La Grotta, Paolo Limone, Giorgio Borretta, Marco Volante, Mauro Papotti, Anna Pia, Massimo Terzolo, Mario Morino, Barbara Pasini, Franco Veglio, Ezio Ghigo, Emanuela Arvat, Mauro Maccario

Summary: This study aimed to develop a simplified scoring system to help assess the recurrence risk of pheochromocytoma patients after surgery. Analysis of previous data revealed tumor size, genetic testing result, age, and PASS value as independent variables associated with recurrence.

BIOMEDICINES (2022)

Article Biochemistry & Molecular Biology

Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

Sarah Allegra, Soraya Puglisi, Chiara Borin, Francesco Chiara, Vittoria Basile, Anna Calabrese, Giuseppe Reimondo, Silvia De Francia

Summary: This study aimed to evaluate the effects of gender on lipoprotein and lipid levels during mitotane adjuvant treatment. The results suggest that gender and personalized approaches may be useful in preventing and managing alterations in the lipid profile.

BIOMEDICINES (2022)

Review Endocrinology & Metabolism

Our experience with the management of patients with non-metastatic adrenocortical carcinoma

Massimo Terzolo, Martin Fassnacht

Summary: Surgery remains the most important therapeutic option for non-metastatic ACC, with the surgeon's expertise being more important than surgical technique. For patients at low risk of recurrence, active surveillance can spare them from unnecessary adjuvant mitotane treatment, while those at moderate-to-high risk should ideally enroll in the ongoing ADIUVO2 trial. Prospective multicenter trials are needed for long-term improvement of patient care.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)

Article Endocrinology & Metabolism

European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors

Martin Fassnacht, Stylianos Tsagarakis, Massimo Terzolo, Antoine Tabarin, Anju Sahdev, John Newell-Price, Iris Pelsma, Ljiljana Marina, Kerstin Lorenz, Irina Bancos, Wiebke Arlt, Olaf M. Dekkers

Summary: Adrenal incidentalomas are adrenal masses detected on imaging for non-suspected adrenal disease. A revision of the first international guidelines on incidentalomas has been provided, focusing on assessing risk of malignancy, managing mild autonomous cortisol secretion, deciding surgical treatment, and determining follow-up for nonoperated patients. Key recommendations include dedicated adrenal imaging for each adrenal mass, thorough clinical and endocrine work-up to exclude hormone excess, consideration of surgical treatment for patients with mild autonomous cortisol secretion and relevant comorbidities, and appropriate surgical intervention guided by risk of malignancy and hormone excess.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2023)

Article Biochemistry & Molecular Biology

Albumin/Mitotane Interaction Affects Drug Activity in Adrenocortical Carcinoma Cells: Smoke and Mirrors on Mitotane Effect with Possible Implications for Patients' Management

Aurora Schiavon, Laura Saba, Gianluca Catucci, Jessica Petiti, Soraya Puglisi, Chiara Borin, Giuseppe Reimondo, Gianfranco Gilardi, Claudia Giachino, Massimo Terzolo, Marco Lo Iacono

Summary: This study found that albumin can bind to mitotane and block its biological activity, leading to altered drug effects. This discovery may contribute to the individualized treatment of rare tumors with mitotane.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

暂无数据